Relmada Therapeutics (NASDAQ:RLMD) announces positive results from a Phase 2 clinical trial
evaluating REL-1017 (dextromethadone) in adult patients with major
depressive disorder (MDD) who have failed to respond adequately to as
many as three prior courses of treatment with antidepressant medication.
The study assessed two daily doses (25 mg and 50 mg) as adjunctive
treatment.
Participants in both dose arms experienced
statistically significant improvements in their depression compared to
placebo across all efficacy measures (four scales) with a favorable
safety profile.
The company plans to meet with the FDA to clarify a registration path.
Fast Track-tagged dextromethadone is an orally
administered NMDA receptor antagonist. The company says it does not have
the unwanted psychomimetic side effects of ketamine.
Shares up 84% premarket on increased volume, albeit on turnover of only 14K shares.
https://seekingalpha.com/news/3505730-relmada-84-percent-premarket-positive-relminus-1017-data-treatment-resistant-depression
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.